Skip to content

Rational Engineering of Notch1 Signaling to Boost the Proliferation of CD19-BBζ CAR-T.

Sep 2026 · Blood · 0 citations
Medicine

TL;DR

A critical role of Notch1 in CAR-T effector function is demonstrated and a novel strategy to augment endogenous Notch1 activity by leveraging native gene regulation is provided to augment endogenous Notch1 activity by leveraging native gene regulation.

Abstract

CAR T-cells targeting CD19 have revolutionized the treatment of relapsed/refractory B-cell malignancies. However, approximately 50% of patients relapse. Patient-derived data indicates that CD19+ relapse is linked to poor CAR T-cell proliferation and/or persistence. We aimed to improve CD19-CAR T-cell survival by manipulating Notch1, a receptor that is activated following T-cell receptor ligation and is essential for upregulating pro-inflammatory and survival genes in T-cells. However, its role in the context of CAR T-cells remains poorly understood. We found that both lentiviral overexpression of Notch1's intracellular domain (N1ICD) and Notch1 genetic knockout resulted in defective CAR-T cell activation and proliferation. This suggests that CAR T-cells require a precise, balanced level of Notch1 signaling for strong effector function. The PEST domain, located at the most distal C-terminus of the Notch1 intracellular domain, regulates the receptor's half-life through ubiquitylation. To augment the levels of active Notch1 and prolong the receptor's signaling, we genetically deleted this domain in the endogenous N1ICD of CAR T-cells. Notch1 PEST-deleted CAR T-cells showed enhanced proliferation post-activation, leading to increased cytotoxicity against CD19+ tumors in vitro. Transcriptionally, Notch1 PEST deletion resulted in upregulation of interferon response pathways and proliferative genes during CAR activation, consistent with Notch1 activation. In B-ALL xenograft in vivo models, treatment with Notch1 PEST-deleted CAR T-cells resulted in greater tumor reduction and increased CAR-T expansion compared to control CAR T-cells. Our findings demonstrate a critical role of Notch1 in CAR-T effector function and provide a novel strategy to augment endogenous Notch1 activity by leveraging native gene regulation.

View source

Similar papers

Open access Sep 2026

Targeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells

The therapeutic efficacy of chimeric antigen receptor T (CAR-T) cells targeting CD19 in chronic lymphocytic leukemia (CLL) treatment can be limited by target cell antigen loss. This study aims to elucidate how the intrinsic NOTCH1 signaling activity in CLL cells modulates their sensitivity to CD19-targeted CAR-T...

Hui-Jian Zheng, Hua-Jian Xian, Chao-Qun Lu et al. · 0 citations
Open access Sep 2026

PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model.

B-cell targeting CAR-T cells (CAR-T) therapies achieve high remission rates, yet durable responses occur in fewer than 40% of patients. Deletion of negative T-cell regulators such as PTPN2, a key inhibitor of TCR and cytokine signaling, represents a promising strategy to enhance CAR-T efficacy. While transfer of PTPN2-...

Francesca Alvarez-Calderon, R. Fleming, Marlana B. Winschel et al. · 0 citations
Open access Aug 2026

C-terminus CD28 phosphorylation, Y218, modulates IL-2 secretion and therapeutic effect of CAR-T cells.

CD28 is a co-stimulatory component of several second-generation chimeric antigen receptor (CAR)-T cells, providing signals essential for T cell proliferation, survival, and cytokine secretion. However, the specific contribution of individual CD28 intracellular motifs to CAR-T cell function remains incompletely understo...

Elena Martinez-Planes, M. C. Ramello, Miguel G. Fontela et al. · 0 citations
Review Open access Aug 2026

Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC.

This work summarizes how costimulatory domains can mediate the persistence, function, and therapeutic potential of CAR-T cells in triple-negative breast cancer (TNBC), a highly aggressive malignancy with limited treatment options and an immunosuppressive tumor microenvironment. Although CAR-T cell therapy has produced...

Hany E. Marei, G. Pozzoli, C. Cenciarelli · 0 citations
Review Open access Sep 2026

Dysfunction of CD58 in tumor immune evasion: from mechanistic regulation to therapeutic resistance

CD58, the primary ligand of the co-stimulatory receptor CD2, plays a crucial role in the formation of the immunological synapse (IS) and the initiation of antitumor immunity involving T cells and natural killer (NK) cells. Aberrant CD58 expression, resulting from genomic inactivation, epigenetic silencing, transcript...

Peng-Fei Guo, Ming Yi, Yu-Jie Gan et al. · 0 citations
Review Open access Sep 2026

CD97/ADGRE5 in Cancer: Structural Activation, Context-Dependent Signaling, and Therapeutic Targeting

CD97 is an adhesion G-protein-coupled receptor encoded by ADGRE5 that integrates extracellular signals (including cell adhesion, ligand binding, and mechanical stimulation) with intracellular signal transduction and is involved in tumor stemness, invasion, metastasis, and cell survival through adhesion-related signalin...

Yu-Hong Lei, Yuan Zhang, Yu-Feng Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.